Drug Trial Radar · NCT07177209
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,000
Actual
Start
Apr 1, 2026
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
Conditions
- Ulcerative Colitis
Interventions
Non-Interventional StudyDrug
As provided in real world practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients that achieve early control of inflammation on conventional therapeutics within 6-24 months of UC diagnosis.Time frame: 6-24 months from UC diagnosis.
- Difference in proportion of patients with inadequate control of inflammation (defined as two or more episodes of raised CRP or faecal calprotectin) treated with conventional therapeutics versus treatment escalation 24 months post UC diagnosis.Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer
Tadworth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.